Enochian Biosciences, Inc.
ENOB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.00 | -5.42 | 0.17 |
| FCF Yield | -2.30% | -6,938.14% | 2,796,758.70% | -0.61% |
| EV / EBITDA | 20.33 | -3.81 | -103.65 | -94.55 |
| Quality | ||||
| ROIC | 32.01% | 1,135.60% | -4.36% | -5.14% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.48 | 0.01 | -7.86 | 0.35 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 100.00% | -100.25% | 461,155,576.13% | -26.95% |
| Safety | ||||
| Net Debt / EBITDA | 0.70 | -0.09 | -1.48 | -1.34 |
| Interest Coverage | -27.03 | 224.32 | -22.02 | 45.97 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |